Enfuvirtide: Patient acceptance and strategies for managing injection-site reactions

AIDS Reader

Volumn 16, Issue 9, 2006, Pages

  Rice, Chris ^a   Wilantewicz, Heather ^b  

^a Vista Medical Partners   (United States)

^b Medical Services   (United States)

Author keywords

Antiretroviral therapy; Enfuvirtide; Entry inhibitor; HIV AIDS; Injection site reactions

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SELF ADMINISTRATION; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SCLEROSIS; INJECTION SITE SWELLING; LIPODYSTROPHY; NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SKIN CYST; VIRUS LOAD; VOMITING; ARTICLE; DRUG ERUPTION; SUBCUTANEOUS DRUG ADMINISTRATION;

DRUG ERUPTIONS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; SELF ADMINISTRATION;

EID: 33750121856     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Cohen C, Green J, Wintfeld N, Patel K. Patient acceptance with self-injection of enfuvirtide (ENF) for HIV over 48 weeks of treatment. Presented at the 9th European AIDS Conference; October 25-29, 2003; Warsaw. Poster 7.1/1.
2. Goodly JDR, Khoo K, Mazikewich A, Thommes J. Optimal adherence to enfuvirtide achieved in the US Early Access Program. Presented at the 7th International Congress on Drug Therapy in HIV Infection; November 14-18, 2004; Glasgow, UK. Poster P130.
3. Clotet BR, Cooper D, Delfraissy JF, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137-1146.
4. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993;9:1051-1053.
5. Greenberg M, Cammack N, Salgo M, Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol. 2004;14:321-337.
6. Liu S, Lu H, Niu J, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem. 2005;280:11259-11273.
7. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther. 2002;72:10-19.
8. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [published correction appears in N Engl J Med. 2003; 349:1100]. N Engl J Med. 2003;48:2175-2185.
9. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348:2186-2195.
10. Trottier B, Arasteh K, Henry K, et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003. Chicago. Abstract H-835.
11. Katlama CA, Clotet B, Cooper D, et al. Enfuvirtide TORO studies: 48-week results confirm 24-week findings. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract LB2.
12. Cohen C, Demasi R, Greenberg M, et al. Selection of non-enfuvirtide (ENF) versus ENF-containing regimens leads to higher failure rates and loss of future antiretroviral (ARV) treatment options. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster H-580.
13. Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16. 2003; Paris. Abstract 116.
14. Walmsley S, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. Presented at the 9th European AIDS Conference; October 25-29, 2003; Warsaw. Abstract 7.3/15.
15. Foy K, Juethner SN. Enfuvirtide (T-20): potentials and challenges. J Assoc Nurses AIDS Care. 2004;15:65-71.
16. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials. 2003;4:347-357.
17. Cohen Q, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327-335.
18. Green J, Kleinman L, Ciesla G, et al. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clin Trials. 2002;3:387-395.
19. Eron JJ, Delfraissy JF, Kuritzkes D, et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract H-836.
20. AmfAR. National amFAR survey. Presented at the 17th National HIV/AIDS Update Conference; April 10-13, 2005; Oakland, Calif.
21. Home R, Fisher M. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced patients: understanding physician and patient perspectives. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro. Poster WePe12.2C12.
22. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr. 2004;37:1140-1146.
23. Clumeck NC, Thompson M, Molina JM, et al. Impact of enfuvirtide on health-related quality of life at 48 weeks. Presented at the 9th European AIDS Conference; October 25-29, 2003; Warsaw. Poland, Poster 7.3/19.
24. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023-1035.
25. Witek J, Rockstroh J, Donatacci L, et al. Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Poster WePeB5822.
26. Arastéh K, Lazzarin A, dotet B, et al. TORO: 96 week viiological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1058.
27. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;(30, suppl 2):S171-S176.
28. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999;13:535-544.
29. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother. 2000;34:703-709.
30. Delfraissy FF, Montanger J, Enron J, et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO1 and TORO2 phase 3 trials in highly antiretroviral (ARV) treatment experienced patients. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; Ferbruary 10-14, 2003; Boston. Abstract 568.
31. Ball RA, Kinchelow T; BR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003;49:826-831.
32. Foy K, Bradley-Springer L, Kempner T, et al. Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide. J Assoc Nurses AIDS Care. 2005;16:2-12.
33. True A, Capuano G, Feldman L, Thommes J. Investigation of palliative interventions for the management of injection site reactions associated with administration of enfuvirtide (ENF). Presented at the HIV DART 2004; December 12-16. 2004. Montego Bay, Jamaica. Poster 67.
34. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137-1146.
35. True A, DeMasi R, Falcon R. An evaluation of HIV-patient quality of life (QOL) and tolerability after administration of enfuvirtide (ENF)-based HAART using a smaller needle in a community practice setting (QUALITÉ). Presented at the 3rd Intenational AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro. Poster WePe6.3C09.
36. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using needle-free gas-powered injection system (Biojector). AIDS. 2006;20:719-723.
37. True A, Zhang Y, Chiu YY, et al. Needle-free administration of enfuvirtide with Biojector 2000 demonstrates bioequivalence to standard needle administration. Presented at HIV DART 2004; December 12-16, 2004; Montego Bay, Jamaica. Poster 57.
38. Lazzarin A, De Carli C, Giuliani G, et al. Cost-effectiveness of enfuvirtide in Italy based on 48-week data. Presented at the 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeC4940.
39. Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327-335.
40. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003; 348:2186-2195.
41. Clotet BR, Cooper D, Delfraissy JF, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS. 2004;18:1137-1146.